Design and in vitro biocompatibility of a novel ocular drug delivery device.

about

Drug delivery techniques for treating age-related macular degeneration.Current advances in the treatment of neovascular age-related macular degeneration.How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches.

P2860

Q38161953-C5EBBE6F-2773-4667-8540-97DDBE1F4294 Q38902191-1D4308E6-AC69-4E60-9E6D-157BF0C98285 Q48902538-3602A468-9775-4D81-B574-B84CDA7E8C42

P2860

Design and in vitro biocompatibility of a novel ocular drug delivery device.

Item

http://www.wikidata.org/entity/Q39870330

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Design and in vitro biocompatibility of a novel ocular drug delivery device.

@en

Design and in vitro biocompatibility of a novel ocular drug delivery device.

@nl

type

Item

label

Design and in vitro biocompatibility of a novel ocular drug delivery device.

@en

Design and in vitro biocompatibility of a novel ocular drug delivery device.

@nl

prefLabel

Design and in vitro biocompatibility of a novel ocular drug delivery device.

@en

Design and in vitro biocompatibility of a novel ocular drug delivery device.

@nl

P1476

Design and in vitro biocompatibility of a novel ocular drug delivery device.

@en

P2093

Balamurali Ambati

http://www.w3.org/2001/XMLSchema#string

Bruce Gale

http://www.w3.org/2001/XMLSchema#string

Dolly J Holt

http://www.w3.org/2001/XMLSchema#string

Nathan Gooch

http://www.w3.org/2001/XMLSchema#string

Randon Michael Burr

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

The biology of VEGF and its receptors

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

Biodegradable polymers for ocular drug delivery.

VEGF-A and the induction of pathological angiogenesis.

VEGF-targeted therapy: mechanisms of anti-tumour activity.

Important causes of visual impairment in the world today.

Formulation and delivery issues for monoclonal antibody therapeutics.

Intraocular implants for extended drug delivery: therapeutic applications.

An experimental platform for systemic drug delivery to the retina.

P304

14-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/JFB4010014

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263324399

http://www.w3.org/2001/XMLSchema#string

P698

24955828

http://www.w3.org/2001/XMLSchema#string

P921

drug delivery

P932

4030910

http://www.w3.org/2001/XMLSchema#string

Design and in vitro biocompatibility of a novel ocular drug delivery device.

about

P2860

P2860

Design and in vitro biocompatibility of a novel ocular drug delivery device.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932